STOCK TITAN

Titan Medical to Present at the H.C. Wainwright Global Investment Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Titan Medical Inc. (Nasdaq: TMDI) announced it will present an overview of its Enos™ robotic single access surgical system at the H.C. Wainwright Global Investment Hybrid Conference from September 12-14, 2022, in New York and virtually. CEO Cary Vance, CFO Stephen Lemieux, and VP Kristen Galfetti will represent the company. The presentation will be available on-demand on September 12 at 7:00 am ET on the company's Investor Relations webpage. Titan aims to enhance robotic-assisted surgery, primarily targeting gynecologic indications with the Enos system.

Positive
  • None.
Negative
  • None.

TORONTO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS) system, today announced the company will present an overview of its Enos™ robotic single access surgical system at the H.C. Wainwright Global Investment Hybrid Conference, taking place September 12-14, 2022 at the Lotte New York Palace Hotel in New York, NY, and virtually.

Cary Vance, Titan’s President and Chief Executive Officer will provide a company overview and participate in investor meetings with Stephen Lemieux, Titan’s Chief Financial Officer, and Kristen Galfetti, Vice President of Investor Relations and Corporate Communications.

Titan Medical’s presentation will be available on-demand September 12th at 7:00 am ET, and available via webcast and replay on the Investor Relations Events section of the company’s website at https://ir.titanmedicalinc.com/news-events/ir-calendar.

About Titan Medical

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company headquartered in Toronto, Ontario and with operations in Chapel Hill, North Carolina, is focused on enhancing robotic assisted surgery using innovative technology through a single access point. The Enos™ robotic single access surgical system is being developed with an ergonomic focus to provide a surgical experience that imitates real-life movements that surgeons demand and includes multi-articulating instruments designed to allow surgeons an increased range of motion in a confined space, with dexterity and the ability to exert the forces necessary to complete common surgical tasks. With the Enos system, Titan intends to initially pursue gynecologic surgical indications.

Enos™ is a trademark of Titan Medical Inc.

For more information, visit www.titanmedicalinc.com and follow @TitanMedical on Twitter and LinkedIn.

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws, which reflect the current expectations of management of the company’s future growth, results of operations, performance and business prospects and opportunities. Forward-looking statements are frequently, but not always, identified by words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions, although these words may not be present in all forward-looking statements. Forward-looking statements that appear in this release may include, without limitation, references to: the company’s focus on the development of surgical technologies for robotic single access surgery; the Enos system providing a surgical experience that imitates real-life movements; the company’s intention to initially pursue gynecologic surgical indications with the Enos system. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the company’s Annual Report for the fiscal year ended December 31, 2021 (which may be viewed at www.sedar.com and at www.sec.gov). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, the company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Contact
Kristen Galfetti
Vice President, Investor Relations & Corporate Communications
+1-781-869-2553
investors@titanmedicalinc.com

###


FAQ

When is Titan Medical presenting at the H.C. Wainwright Global Investment Hybrid Conference?

Titan Medical will present at the conference from September 12-14, 2022.

Who will represent Titan Medical at the conference?

Cary Vance, Stephen Lemieux, and Kristen Galfetti will represent Titan Medical.

What is the focus of Titan Medical's Enos™ robotic system?

The Enos™ robotic system focuses on enhancing robotic-assisted surgery, initially targeting gynecologic indications.

What time will the Enos presentation be available on-demand?

The presentation of the Enos™ system will be available on-demand on September 12 at 7:00 am ET.

Where can I watch the Titan Medical presentation?

You can watch the presentation on the Investor Relations Events section of Titan Medical's website.

TMDI

NASDAQ:TMDI

TMDI Rankings

TMDI Latest News

TMDI Stock Data

16.07M
111.59M
0.08%
4.56%
0.05%
Medical Devices
Healthcare
Link
Canada
Toronto